Market Overview

Stifel Terminates Coverage On Oncolytics Biotech Due To Reallocation Of Resources

Share:

In a report published Monday, Stifel analyst Brian Klein terminated coverage on Oncolytics Biotech (NASDAQ: ONCY).

In the report, Stifel noted, "Due to a reallocation of resources, we are discontinuing coverage of Oncolytics Biotech Inc. (ONCY). Our most recent rating of Hold should no longer be used as an indicator for the company going forward."

Oncolytics Biotech closed on Friday at $0.42.

Latest Ratings for ONCY

DateFirmActionFromTo
May 2020RBC CapitalMaintainsOutperform
Sep 2013NeedhamInitiates Coverage onBuy
Mar 2013PiperJaffrayInitiates Coverage onOverweight

View More Analyst Ratings for ONCY
View the Latest Analyst Ratings

 

Related Articles (ONCY)

View Comments and Join the Discussion!

Posted-In: Brian Klein StifelAnalyst Color Termination Analyst Ratings

Latest Ratings

StockFirmActionPT
MSFTDeutsche BankMaintains250.0
PINSDeutsche BankMaintains75.0
CTSHDeutsche BankMaintains71.0
EBAYDeutsche BankMaintains59.0
KLACDeutsche BankMaintains205.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com